Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025
[243 Pags Report] The global drug discovery services market size is projected to reach USD 21.4 billion by 2025 from USD 11.1 billion in 2020, at a CAGR of 14.0% during the forecast period. growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, thus necessitating increasing demand for outsourcing analytical testing and clinical trial services. Initiatives for research on rare diseases and orphan drugs, and focus on drug discovery are driving the growth of the global drug discovery services industry. Growth in biologics, patent expiries and emerging economies are expected to provide a wide range of growth opportunities for players in the market.
To know about the assumptions considered for the study, Request for Free Sample Report
covid-19 impact on the global drug discovery services market
The COVID-19 outbreak is an unprecedented global public health challenge and is expected to have a significant impact on the ISH market for diagnostics and research applications.
In order to expedite the research and development process, leading pharmaceutical and biotechnology companies are entering into a collaboration and partnership program with drug discovery services firms to develop vaccines and therapeutics to combat coronavirus. For instance, Eurofins has joined hands with pharmaceutical and biotech companies to support and identify potential drug molecules. Some of the services offered by Eurofins include safety profiling, drug repositioning services, custom assay development, efficacy testing, and cytokine storm assessment. In June 2020, Covance entered into a partnership with Medable to accelerate the adoption of decentralized clinical trial technology. In June 2020, Covance also launched a COVID-19 clinical trial platform in the US to provide information about COVID-19 trails and to speed up the recruitment process for clinical research.
Such strategies and initiatives by drug discovery services firms will accelerate the growth of this market during the forecast period.
Drug Discovery Services Market Dynamics
Driver: Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
R&D activity has grown significantly in the pharmaceutical and biopharmaceutical industry. In 2017, the pharmaceutical industry alone spent USD 149.8 billion on R&D (Source: International Federation of Pharmaceutical Manufacturers & Associations). Also, pharmaceutical companies spend, on average, 17% of their revenue on R&D.
Pharmaceutical, biopharmaceutical, and medical device companies invest heavily in the development of novel drugs and devices, with most of the expenditure concentrated on phase III and the preclinical stages of drug development. Growth in R&D expenditure, fueled by the need for numerous preclinical and clinical services during the drug discovery and development process, is one of the major factors propelling the drug discovery services market, globally.
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) Annual Membership Survey (2018), the R&D expenditure of PhRMA members increased to USD 71.4 billion in 2017 from USD 59.6 billion in 2015. Further increases in R&D spending in the coming years will provide a significant boost to drug discovery and development activities, which will ensure the growth of the drug discovery services market in the forecast period.
Restraints: High cost of drug discovery and development
Drug discovery and development involve high costs due to the high attrition rate of drug candidates in development. Since R&D for some rare diseases is very challenging and requires a specific group of people to conduct a clinical trial, drug R&D processes can be prone to failure. In addition, only 7 of 100 cancer drugs that reach the clinical testing phase end up gaining regulatory approval; most drugs fail long before this point. From drug discovery through FDA approval, developing a new medicine, on average, takes 1015 years and costs USD 2.6 billion. Less than 12% of the candidate medicines that make it to phase I clinical trials are approved by the FDA (Source: Biopharmaceuticals in Perspective, Summer 2019).
In addition, high financial costs, difficulties in the recruitment and retention of participants, insufficiencies in the clinical research workforce, drug sponsor-imposed barriers, regulatory and administrative barriers, disconnect between clinical research and medical care, and barriers related to the globalization of clinical research may also negatively affect the overall drug development process. This compels companies to invest in the development of generics instead of new drug development
Opportunity: Growth in biologics market
Many companies are investing heavily in the development of biologics. Currently, more than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. As newer biologics are being discovered or are in the pipeline, pharmaceutical and biopharmaceutical companies are heavily investing in their R&D. CROs have also become important in this field as providers of specialized services, such as drug discovery services, for biologics.
According to the US FDA, the number of new biologic approvals in the US increased from 41 in 2014 to 59 in 2018. This is nearly double the 10-year (20092017) average of 33 new molecular entities (NME) approvals by the Center for Drug Evaluation and Research (CDER). Growing investments by biopharmaceutical companies to develop biologics are further expected to increase the number of approved products worldwide.
The approval pathway for a biologic is more stringent than that for generic medicines, as, unlike chemically synthesized APIs, establishing bioequivalence for a biotech-based API is difficult and complex. Thus, compared to small molecules, biologics require specialized testing services. This will offer opportunities for contract research service providers to expand their portfolios and capabilities and offer drug discovery services
By drug type, Small molecule drugs accounted for the largest share in the drug discovery services market
Based on drug type, the drug discovery services market is segmented into small-molecule drugs and biologic drugs. In 2019, small molecule drugs are accounted for the largest market share as small-molecule drugs are simple, well-defined, and easy to characterize. Due to these features, they can quickly enter cells, affect molecules, and cause cancer cells to die.
By therapeutic area, Oncology segment accounted for the largest share of the drug discovery services market
Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. The oncology segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the increasing number of patients who have cancer and the subsequent increase in the demand for cancer therapies.
By Type,Medicinal Chemistry accounted for the largest share of the drug discovery services market
Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). Of all these type segments, the medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market in 2020. The large share of this segment is due to factors such as the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates. Furthermore, the extensive usage of medicinal chemistry in academics, biotechnology companies, and large pharmaceutical companies are also supporting market growth.
North America accounted for the largest share of the drug discovery services market in 2019
Based on the region, the global drug discovery services market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2019, North America accounted for the largest share of the drug discovery services market. The large share of this market segment can be attributed majorly to the presence of well-established CROs, rising R&D expenditure by pharmaceutical & biopharmaceutical companies, and the availability of latest techniques, instruments, and facilities for drug discovery research.
To know about the assumptions considered for the study, download the pdf brochure
Some of the key players include Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec A.G. (Germany), Domainex (UK), GenScript Biotech Corporation (China), Laboratory Corporation of America Holdings (US), WuXi AppTec (China), Pharmaceutical Product Development, LLC (US), Jubilant Biosys Ltd. (India), Eurofins Scientific SE (Luxembourg), Piramal Enterprises Ltd. (India), and Selvita S.A. (Poland)
Scope of the report
|
Report Metric |
Details |
|
Market Size Available for Years |
20182025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
20202025 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Process, Type, Drug Type, Therapeutic Area and Region |
|
Geographies Covered |
North America, Europe, APAC and the RoW |
|
Companies Covered |
The major market players include Thermo Fisher Scientific, Inc. (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec A.G. (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), GVK Biosciences Private Limited (India), Jubilant Life Sciences (India), Laboratory Corporation of America Holdings (US), Lonza Group AG (Switzerland), Piramal Enterprises Ltd. (India), Viva Biotech (China), Dalton Pharma Services (Canada), (Domainex (UK), Selvita S.A. (Poland), SRI International (US), and BioDuro (US). |
The study categorizes the ISH market into the following segments and subsegments:
By Process
- Target Selection
- Target Validation
- Hit-To-Lead Identification
- Lead Optimization
- Candidate Validation
By Type
- Medicinal Chemistry
- Biology Services
- Drug Metabolism and Pharmacokinetics (DMPK)
By Drug Type
- Small Molecules
- BiologicsInfectious Disease Diagnostics
By Therapeutic Area
- Oncology
- Neurology
- Infectious and Immune System Diseases
- Digestive System Diseases
- Cardiovascular Diseases
- Other Therapeutic Areas
By Company Type
- Tier 1 Pharmaceutical Companies
- Tier 2 Pharmaceutical Companies
- Tier 3 Pharmaceutical Companies
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Rest of the World
- Latin America
- The Middle East and Africa
Recent Developments
- In 2020, Covance entered into a partnership with Medable to expedite the adoption of decentralized trial technology
- In 2020, Eurofins entered into partnership with PharmaResources (China). This partnership enabled both companies to build a joint drug discovery platform to accelerate small molecule drug development.
- In 2020, LabCorp launched its extensive preclinical, clinical, and post-approval cell and gene therapy development solutions through Covance, its drug development business
- In 2020, WuXi AppTec Research Service Division and BioSolveIT launched GalaXi, a new chemical space of tangible molecules
- In 2020, Charles River acquired HemaCare to strengthen its Research Models Services segment through Hemacares broad range of human primary cell and cell processing services that support the discovery and development of cell therapies
Frequently Asked Questions (FAQ):
What are the growth opportunities in the drug discovery services market across major regions in the future?
Growing Biologics market and patent epiries provides growth opportunities to drug discovery services market
Emerging countries have immense opportunities for the growth and adoption of drug discovery services. Will this scenario continue during the next five years?
Emerging markets also provide room for innovation. China, in particular, has a large, well-educated talent pool, with substantial government and private funding in the countrys pharmaceutical industry. This has resulted in many large pharmaceutical companies establishing state-of-the-art research facilities in China to drive the next breakthrough drug discoveries in conjunction with other Asian countries such as India
Which is the process that has largsest market share in the overall market?
In 2019, the hit-to-lead identification segment accounted for the largest share of the drug discovery services market.
By drug type, which is the largest market share in the drug discovery services market?
On the basis of drug type, the drug discovery services market is segmented into small-molecule drugs and biologic drugs. In 2019, the small-molecule drugs segment accounted for the largest share of the drug discovery services market.
Which therapeutic area is the largest market share in the drug discovery services market?
On the basis of therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. In 2019, the oncology segment accounted for the largest share of the market. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 35)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 DRUG DISCOVERY SERVICES MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 38)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4 BOTTOM-UP APPROACH
2.2.2 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 5 TOP-DOWN APPROACH
2.2.3 GROWTH FORECAST
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 7 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2020 VS. 2025 (USD MILLION)
FIGURE 8 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2020 VS. 2025
FIGURE 9 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2020 VS. 2025 (USD MILLION)
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY REGION
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
FIGURE 12 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE & COUNTRY (2020)
FIGURE 13 SMALL-MOLECULE DRUGS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN DRUG DISCOVERY SERVICES MARKET IN 2020
4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 52)
5.1 INTRODUCTION
TABLE 1 DRUG DISCOVERY PROCESS OVERVIEW
5.2 MARKET DYNAMICS
FIGURE 15 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
5.2.1 DRIVERS
5.2.1.1 Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
FIGURE 16 R&D SPENDING OF PHARMA MEMBER COMPANIES, 20012018 (USD BILLION)
5.2.1.2 Increasing demand for outsourcing analytical testing and clinical trial services
FIGURE 17 ACTIVE PHARMACEUTICAL PIPELINE, JANUARY 2009JANUARY 2019
5.2.1.3 Initiatives for research on rare diseases and orphan drugs
TABLE 2 RESEARCH PROJECTS FUNDED BY THE IRDIRC
FIGURE 18 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (20102017)
5.2.1.4 Focus on drug discovery
FIGURE 19 NUMBER OF REGISTERED STUDIES (20052017)
5.2.2 RESTRAINTS
5.2.2.1 High cost of drug discovery and development
TABLE 3 AVERAGE COST OF DRUGS APPROVED PER YEAR, 20042013
FIGURE 20 AVERAGE COST TO DEVELOP ONE NEW APPROVED DRUGINCLUDING THE COST OF FAILURES
5.2.2.2 Stringent regulations governing drug discovery and animal usage
5.2.3 OPPORTUNITIES
5.2.3.1 Growth in the biologics market
5.2.3.2 Patent expiries
5.2.3.3 Emerging markets
5.2.4 TRENDS
5.2.4.1 Growing adoption of artificial intelligence-based tools for drug discovery
5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS (Page No. - 63)
6.1 INTRODUCTION
TABLE 4 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 5 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
6.2 TARGET SELECTION
6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET
TABLE 6 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 20162019 (USD MILLION)
TABLE 7 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 20202025 (USD MILLION)
6.3 TARGET VALIDATION
6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 8 ADVANTAGES AND DISADVANTAGES OF SIRNA
TABLE 9 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 20162019 (USD MILLION)
TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 20202025 (USD MILLION)
6.4 HIT-TO-LEAD IDENTIFICATION
6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET
TABLE 11 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 20162019 (USD MILLION)
TABLE 12 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 20202025 (USD MILLION)
6.5 LEAD OPTIMIZATION
6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS
TABLE 13 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 20162019 (USD MILLION)
TABLE 14 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 20202025 (USD MILLION)
6.6 CANDIDATE VALIDATION
6.6.1 CANDIDATE VALIDATION SEGMENT TO GROW AT A HIGH CAGR DURING THE FORECAST PERIOD
TABLE 15 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 20162019 (USD MILLION)
TABLE 16 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY REGION, 20202025 (USD MILLION)
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE (Page No. - 71)
7.1 INTRODUCTION
TABLE 17 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 18 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
7.2 MEDICINAL CHEMISTRY SERVICES
7.2.1 WIDE APPLICATIONS OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY ARE A MAJOR FACTOR DRIVING MARKET GROWTH
TABLE 19 MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION, 20162019 (USD MILLION)
TABLE 20 MEDICINAL CHEMISTRY DRUG DISCOVERY SERVICES MARKET, BY REGION, 20202025 (USD MILLION)
7.3 BIOLOGY SERVICES
7.3.1 RESTRICTIONS ON THE USAGE OF ANIMALS IN RESEARCH ACTIVITIES MAY LIMIT MARKET GROWTH
TABLE 21 BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 20162019 (USD MILLION)
TABLE 22 BIOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 20202025 (USD MILLION)
7.4 DRUG METABOLISM & PHARMACOKINETICS
7.4.1 DMPK STUDIES ARE EMPLOYED AT THE DISCOVERY, CANDIDATE SELECTION, INVESTIGATIONAL NEW DRUG, AND NEW DRUG APPLICATION STAGES
TABLE 23 DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION, 20162019 (USD MILLION)
TABLE 24 DMPK DRUG DISCOVERY SERVICES MARKET, BY REGION, 20202025 (USD MILLION)
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE (Page No. - 77)
8.1 INTRODUCTION
TABLE 25 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 26 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
8.2 SMALL-MOLECULE DRUGS
8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET DURING THE FORECAST PERIOD
TABLE 27 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 20162019 (USD MILLION)
TABLE 28 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY REGION, 20202025 (USD MILLION)
8.3 BIOLOGIC DRUGS
8.3.1 HIGH SET-UP COSTS OF THE INSTRUMENTS REQUIRED FOR BIOLOGIC DRUG MANUFACTURING MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT
TABLE 29 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 20162019 (USD MILLION)
TABLE 30 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 20202025 (USD MILLION)
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 82)
9.1 INTRODUCTION
TABLE 31 GLOBAL NUMBER OF CLINICAL TRIALS, BY THERAPEUTIC AREA (AS OF OCTOBER 2019)
FIGURE 21 R&D PIPELINE, BY THERAPY GROUP, 2018 & 2019
TABLE 32 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 33 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
9.2 ONCOLOGY
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH
FIGURE 22 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY, BY REGION (AS OF DECEMBER 2019)
TABLE 34 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 20162019 (USD MILLION)
TABLE 35 DRUG DISCOVERY SERVICES MARKET FOR ONCOLOGY, BY REGION, 20202025 (USD MILLION)
9.3 NEUROLOGY
9.3.1 INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH
TABLE 36 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION, 20162019 (USD MILLION)
TABLE 37 DRUG DISCOVERY SERVICES MARKET FOR NEUROLOGY, BY REGION, 20202025 (USD MILLION)
9.4 INFECTIOUS AND IMMUNE SYSTEM DISEASES
9.4.1 EMERGENCE OF NEW INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 38 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 20162019 (USD MILLION)
TABLE 39 DRUG DISCOVERY SERVICES MARKET FOR INFECTIOUS AND IMMUNE SYSTEM DISEASES, BY REGION, 20202025 (USD MILLION)
9.5 DIGESTIVE SYSTEM DISEASES
9.5.1 AS THERE IS A HUGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES, PHARMACEUTICAL COMPANIES ARE INVESTING SIGNIFICANTLY IN R&D FOR THE DEVELOPMENT OF INNOVATIVE DRUGS
TABLE 40 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 20162019 (USD MILLION)
TABLE 41 DRUG DISCOVERY SERVICES MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 20202025 (USD MILLION)
9.6 CARDIOVASCULAR DISEASES
9.6.1 HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS
TABLE 42 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 20162019 (USD MILLION)
TABLE 43 DRUG DISCOVERY SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 20202025 (USD MILLION)
9.7 OTHER THERAPEUTIC AREAS
TABLE 44 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 20162019 (USD MILLION)
TABLE 45 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 20202025 (USD MILLION)
10 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE (Page No. - 94)
10.1 INTRODUCTION
TABLE 46 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20162019 (USD MILLION)
TABLE 47 DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20202025 (USD MILLION)
10.2 TIER 1 PHARMACEUTICAL COMPANIES
TABLE 48 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 20162019 (USD MILLION)
TABLE 49 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 PHARMACEUTICAL COMPANIES, BY REGION, 20202025 (USD MILLION)
10.3 TIER 2 PHARMACEUTICAL COMPANIES
TABLE 50 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 20162019 (USD MILLION)
TABLE 51 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 PHARMACEUTICAL COMPANIES, BY REGION, 20202025 (USD MILLION)
10.4 TIER 3 PHARMACEUTICAL COMPANIES
TABLE 52 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 20162019 (USD MILLION)
TABLE 53 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 PHARMACEUTICAL COMPANIES, BY REGION, 20202025 (USD MILLION)
11 DRUG DISCOVERY SERVICES MARKET, BY REGION (Page No. - 99)
11.1 INTRODUCTION
TABLE 54 DRUG DISCOVERY SERVICES MARKET, BY REGION, 20162019 (USD MILLION)
TABLE 55 DRUG DISCOVERY SERVICES MARKET, BY REGION, 20202025 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 23 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA
FIGURE 24 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
TABLE 56 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20162019 (USD MILLION)
TABLE 57 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20202025 (USD MILLION)
TABLE 58 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 59 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 60 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 61 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 62 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 63 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 64 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 65 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
TABLE 66 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20162019 (USD MILLION)
TABLE 67 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20202025 (USD MILLION)
11.2.1 US
11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market
FIGURE 25 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019)
TABLE 68 NUMBER OF CLINICAL TRIALS STARTED IN THE US, BY COMPANY, 2017
TABLE 69 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 70 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 71 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 72 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 73 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 74 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 75 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 76 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth
TABLE 77 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019)
TABLE 78 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY COMPANY, 2017
TABLE 79 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 80 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 81 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 82 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 83 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 84 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 85 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 86 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.3 EUROPE
TABLE 87 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20162019 (USD MILLION)
TABLE 88 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20202025 (USD MILLION)
TABLE 89 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 90 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 91 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 92 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 93 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 94 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,20202025 (USD MILLION)
TABLE 95 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 96 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
TABLE 97 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20162019 (USD MILLION)
TABLE 98 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20202025 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market
TABLE 99 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 100 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 101 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 102 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 103 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 104 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 105 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 106 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.3.2 UK
11.3.2.1 Investment by pharmaceutical sponsors in the UK for drug discovery services to support market growth
FIGURE 26 UK: PHARMACEUTICAL R&D EXPENDITURE, 20132017
TABLE 107 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 108 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 109 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 110 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 111 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 112 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 113 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 114 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 High number of oncology clinical trials in France to drive market growth
TABLE 115 NUMBER OF CLINICAL TRIALS STARTED IN FRANCE, BY COMPANY, 2017
TABLE 116 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 117 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 118 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 119 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 120 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 121 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 122 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 123 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.3.4 ITALY
11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth
TABLE 124 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY, 2017
TABLE 125 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 126 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 127 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 128 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 129 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 130 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 131 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 132 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
FIGURE 27 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 20112017
TABLE 133 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 134 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 135 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 136 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 137 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 138 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 139 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 140 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 141 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 142 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 143 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 144 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 145 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 146 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 147 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 148 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.4 ASIA PACIFIC
TABLE 149 TOTAL NUMBER OF CLINICAL TRIALS IN THE APAC, BY THERAPEUTIC AREA, 2017
FIGURE 28 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT
TABLE 150 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20162019 (USD MILLION)
TABLE 151 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20202025 (USD MILLION)
TABLE 152 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 153 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 154 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 155 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 156 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 157 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 158 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 159 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Low cost of clinical trials and large pharmaceutical R&D footprint in China to drive market growth
TABLE 160 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 161 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 162 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 163 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 164 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 165 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 166 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 167 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.4.2 INDIA
11.4.2.1 Low-cost services and availability of skilled workforce to support market growth in India
TABLE 168 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 169 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 170 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 171 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 172 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 173 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 174 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 175 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Government initiatives for drug innovation to support market growth in Japan
TABLE 176 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 177 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 178 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 179 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 180 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 181 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 182 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 183 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 184 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 185 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 186 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 187 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 188 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 189 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 190 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 191 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.5 REST OF THE WORLD
TABLE 192 ROW: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20162019 (USD MILLION)
TABLE 193 ROW: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 20202025 (USD MILLION)
TABLE 194 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 195 ROW: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20202025 (USD MILLION)
TABLE 196 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 197 ROW: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 198 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 199 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 200 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 201 ROW: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
TABLE 202 ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20162019 (USD MILLION)
TABLE 203 ROW: DRUG DISCOVERY SERVICES MARKET, BY COMPANY TYPE, 20202025 (USD MILLION)
11.5.1 LATIN AMERICA
11.5.1.1 Increasing investment and R&D to drive market growth in Latin America
TABLE 204 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 20162019 (USD MILLION)
TABLE 205 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY PROCESS 20202025 (USD MILLION)
TABLE 206 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 207 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 208 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 209 ROW: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 210 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 211 LATIN AMERICA : DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
11.5.2 MIDDLE EAST & AFRICA (MEA)
11.5.2.1 Growing pharmaceutical industry to drive market growth in the Middle East and Africa
TABLE 212 MEA : DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 213 MEA : DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 214 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20162019 (USD MILLION)
TABLE 215 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 20202025 (USD MILLION)
TABLE 216 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20162019 (USD MILLION)
TABLE 217 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 20202025 (USD MILLION)
TABLE 218 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20162019 (USD MILLION)
TABLE 219 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 20202025 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 175)
12.1 OVERVIEW
12.2 MARKET SHARE ANALYSIS
FIGURE 29 DRUG DISCOVERY SERVICES MARKET SHARE (2019)
12.3 COMPETITIVE SCENARIO
12.3.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS
TABLE 220 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (20182020)
12.3.2 SERVICE LAUNCHES
TABLE 221 SERVICE LAUNCHES (20182020)
12.3.3 MERGERS & ACQUISITIONS
TABLE 222 MERGERS & ACQUISITIONS (20182020)
12.3.4 EXPANSIONS
TABLE 223 EXPANSIONS (20182019)
12.4 COMPETITIVE EVALUATION MATRIX
12.4.1 STARS
12.4.2 PERVASIVE
12.4.3 DYNAMIC LEADERS
12.4.4 EMERGING COMPANIES
FIGURE 30 GLOBAL DRUG DISCOVERY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
13 COMPANY PROFILES (Page No. - 180)
(Business Overview, Products Offered, Recent Developments, MnM View)*
13.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
FIGURE 31 LABCORP: COMPANY SNAPSHOT (2019)
13.2 EUROFINS SCIENTIFIC SE
FIGURE 32 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2019)
13.3 CHARLES RIVER LABORATORIES INTERNATIONAL
FIGURE 33 CHARLES RIVER LABORATORIES INTERNATIONAL: COMPANY SNAPSHOT (2019)
13.4 EVOTEC SE
FIGURE 34 EVOTEC SE: COMPANY SNAPSHOT (2019)
13.5 THERMO FISHER SCIENTIFIC
FIGURE 35 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
13.6 SYNGENE INTERNATIONAL LIMITED
FIGURE 36 SYNGENE: COMPANY SNAPSHOT (2019)
13.7 JUBILANT LIFESCIENCES
FIGURE 37 JUBILANT LIFESCIENCES: COMPANY SNAPSHOT (2018)
13.8 GENSCRIPT BIOTECH CORPORATION
FIGURE 38 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2019)
13.9 PIRAMAL ENTERPRISES LIMITED
FIGURE 39 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2019)
13.10 WUXI APPTEC
FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2019)
13.11 SELVITA (FORMERLY SELVITA CRO S.A.)
FIGURE 41 SELVITA: COMPANY SNAPSHOT (2019)
13.12 FRONTAGE HOLDINGS
FIGURE 42 FRONTAGE HOLDINGS: COMPANY SNAPSHOT (2019)
13.13 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
FIGURE 43 PHARMACEUTICAL PRODUCT DEVELOPMENT : COMPANY SNAPSHOT (2019)
13.14 SHANGHAI MEDICILON, INC.
13.15 ALBANY MOLECULAR RESEARCH, INC.
13.16 AURIGENE DISCOVERY TECHNOLOGIES (A SUBSIDIARY OF DR. REDDYS LABORATORIES)
13.17 DOMAINEX LTD.
13.18 CHEMPARTNER CO., LTD.
13.19 TCG LIFESCIENCES PVT. LIMITED
13.20 VIVA BIOTECH (SHANGHAI) LTD.
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies
14 ADJACENT RELATED MARKETS (Page No. - 228)
14.1 INTRODUCTION
14.2 LIMITATIONS
14.3 CONTRACT RESEARCH ORGANIZATION (CRO) SERVICE MARKET
14.3.1 MARKET DEFINITION
14.3.2 MARKET OVERVIEW
14.3.3 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY REGION
TABLE 224 CRO SERVICES MARKET, BY REGION, 20172025 (USD MILLION)
14.3.3.1 North America
TABLE 225 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 20182025 (USD MILLION)
14.3.3.2 Europe
TABLE 226 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 20182025 (USD MILLION)
14.3.3.3 Asia Pacific
TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 20182025 (USD MILLION)
14.4 CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) MARKET
14.4.1 MARKET DEFINITION
14.4.2 MARKET OVERVIEW
14.4.3 CTMS MARKET, BY REGION
TABLE 228 CTMS MARKET, BY REGION, 20152022 (USD MILLION)
14.4.3.1 North America
TABLE 229 NORTH AMERICA: CTMS MARKET, BY COUNTRY, 20152022 (USD MILLION)
14.4.3.2 Europe
TABLE 230 EUROPE: CTMS MARKET, BY COUNTRY, 20152022 (USD MILLION)
14.4.3.3 Asia Pacific
TABLE 231 ASIA PACIFIC: CTMS MARKET, BY COUNTRY, 20152022 (USD MILLION)
14.5 DRUG DISCOVERY INFORMATICS MARKET
14.5.1 MARKET DEFINITION
14.5.2 MARKET OVERVIEW
14.5.3 DRUG DISCOVERY INFORMATICS MARKET, BY REGION
TABLE 232 DRUG DISCOVERY INFORMATICS MARKET, BY REGION, 20172025 (USD MILLION)
14.5.3.1 North America
TABLE 233 NORTH AMERICA: DRUG DISCOVERY INFORMATICS MARKET, BY COUNTRY, 20172025 (USD MILLION)
14.5.3.2 Europe
TABLE 234 EUROPE: DRUG DISCOVERY INFORMATICS MARKET, BY COUNTRY, 20172025
14.5.3.3 Asia Pacific
TABLE 235 APAC: DRUG DISCOVERY INFORMATICS MARKET, BY COUNTRY, 20172025 (USD MILLION)
15 APPENDIX (Page No. - 235)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global drug discovery services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the drug discovery services market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from government sources, such as Association of International Contract Research Organizations (AICROS), American Association of Pharmaceutical Scientists (AAPS), Clinical and Contract Research Association (CCRA), Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Pharmaceutical Research and Manufacturers of America (PhRMA), National Center for Biotechnology Information (NCBI), Parenteral Drug Association (PDA), Food and Drug Administration (FDA), Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. Secondary data was collected and analyzed to arrive at the overall size of the global drug discovery services market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global drug discovery services market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical and biopharmaceutical industry) and supply-side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, and channel partners, among others) across four major regionsNorth America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by process, type, drug type, therapeutic area, company type, and region).
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Report Objectives
- To define, describe, and forecast the global drug discovery services market on the basis of process, type, drug type, therapeutic area, company type, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and trends)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall drug discovery services market
- To analyze the opportunities in the market for stakeholders and provide details of
the competitive landscape for market leaders operating in the drug discovery services market - To forecast the revenue of the market with respect to four regional segments, namely,
North America, Europe, the Asia Pacific, and the Rest of The World2 - To profile key market players and comprehensively analyze their service portfolios, market positions, and core competencies3
- To track and analyze competitive developments such as services launches; expansions; agreements, collaborations, & partnerships; and mergers & acquisitions in the drug discovery services market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the clients specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Further Split Of The Drug Discovery Services Market For Latam
- Drug discovery services market size and growth rate estimates for Brazil, Mexico, and Argentina
Get in-depth analysis of the COVID-19 impact on the Drug Discovery Services Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Drug Discovery Services Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Drug Discovery Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Drug Discovery Services Market